agilon health inc AGL.N, AGL is expected to show a fall in quarterly revenue when it reports results on February 25 for the period ending December 31 2025
The Westerville Ohio-based company is expected to report a 4.0% decrease in revenue to $1.461 billion from $1.52 billion a year ago, according to the mean estimate from 15 analysts, based on LSEG data.
LSEG's mean analyst estimate for agilon health inc is for a loss of 27 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 13 "hold" and 2 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for agilon health inc is $1.00, about 128.5% above its last closing price of $0.44
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.16 | -0.16 | -0.27 | Missed | -70.6 |
Jun. 30 2025 | -0.12 | -0.12 | -0.25 | Missed | -116.8 |
Mar. 31 2025 | -0.01 | -0.01 | 0.03 | Beat | 425.7 |
Dec. 31 2024 | -0.23 | -0.23 | -0.26 | Missed | -13.8 |
Sep. 30 2024 | -0.11 | -0.11 | -0.29 | Missed | -173.8 |
Jun. 30 2024 | -0.09 | -0.08 | -0.07 | Beat | 13.3 |
Mar. 31 2024 | -0.03 | -0.01 | -0.01 | Met | 17.8 |
Dec. 31 2023 | -0.32 | -0.30 | -0.41 | Missed | -36.3 |
This summary was machine generated February 23 at 21:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)